Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

ClinicalTrials.gov ID: NCT03611595

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03611595. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A National Phase I Study of Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)

Study identification

NCT ID: NCT03611595
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Peter Zage; Other
Enrollment: 15 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Cabozantinib Drug
13-cis-retinoic acid Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 26 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 28, 2018 (Actual)
Primary completion: Feb 24, 2026 (Actual)
Completion: Mar 23, 2026 (Actual)
Last update posted: May 27, 2026

2018 – 2026

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Rady Children's Hospital - San Diego	San Diego	California	92123	—
Children's Healthcare of Atlanta	Atlanta	Georgia	30322	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03611595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 27, 2026 · Synced Nov 12, 2026